| 51 |
27067333 | Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years. | 2016 Jun |
1 |
| 52 |
27125860 | Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients. | 2016 Dec |
1 |
| 53 |
27333947 | Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers. | 2016 Oct |
6 |
| 54 |
27422672 | Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective. | 2016 Oct |
1 |
| 55 |
27600044 | Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers. | 2016 Nov |
1 |
| 56 |
27627692 | Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects? | 2016 Oct |
2 |
| 57 |
27709010 | Insights into CYP2B6-mediated drug-drug interactions. | 2016 Sep |
1 |
| 58 |
27779789 | Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection. | 2016 Dec |
3 |
| 59 |
25889207 | CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. | 2015 Mar 27 |
1 |
| 60 |
25906774 | The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. | 2015 Apr 25 |
1 |
| 61 |
25948712 | Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase. | 2015 Jul |
2 |
| 62 |
26288843 | Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. | 2015 Jul |
2 |
| 63 |
26415139 | A Global Health Diagnostic for Personalized Medicine in Resource-Constrained World Settings: A Simple PCR-RFLP Method for Genotyping CYP2B6 g.15582C>T and Science and Policy Relevance for Optimal Use of Antiretroviral Drug Efavirenz. | 2015 Jun |
1 |
| 64 |
26681005 | Prevalence of CYP2B6 polymorphisms in Argentinians: the role of genetic testing. | 2015 Dec 11 |
1 |
| 65 |
26779253 | An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. | 2015 |
1 |
| 66 |
23629159 | Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. | 2014 Apr |
1 |
| 67 |
23990572 | Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. | 2014 Feb 1 |
1 |
| 68 |
24142869 | Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. | 2014 Jan |
3 |
| 69 |
24316028 | The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. | 2014 Feb |
5 |
| 70 |
24390631 | Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. | 2014 Apr |
2 |
| 71 |
24497997 | Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. | 2014 |
3 |
| 72 |
24820076 | Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6. | 2014 Jul |
1 |
| 73 |
24956253 | Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. | 2014 May |
2 |
| 74 |
25096076 | Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. | 2014 Dec |
4 |
| 75 |
25309681 | Structure-Activity Studies Reveal the Oxazinone Ring Is a Determinant of Cytochrome P450 2B6 Activity Toward Efavirenz. | 2014 Oct 9 |
7 |
| 76 |
25394049 | Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial. | 2014 |
1 |
| 77 |
23254426 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. | 2013 Feb |
1 |
| 78 |
23385314 | In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. | 2013 |
2 |
| 79 |
23467454 | Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. | 2013 |
1 |
| 80 |
23640958 | Efavirenz intoxication due to a new CYP2B6 constellation. | 2013 |
1 |
| 81 |
23846872 | CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. | 2013 Dec |
1 |
| 82 |
24521642 | Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients. | 2013 Dec |
1 |
| 83 |
25505649 | Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. | 2013 |
1 |
| 84 |
22398970 | Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. | 2012 Apr |
1 |
| 85 |
22950382 | Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand. | 2012 Dec |
1 |
| 86 |
21301907 | Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods. | 2011 Nov |
2 |
| 87 |
21395646 | In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. | 2011 Apr |
2 |
| 88 |
21659470 | Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. | 2011 Sep |
7 |
| 89 |
21821736 | Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262. | 2011 Nov |
2 |
| 90 |
20001610 | Efavirenz in the therapy of HIV infection. | 2010 Jan |
2 |
| 91 |
20338069 | Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. | 2010 Mar 26 |
2 |
| 92 |
20860463 | Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. | 2010 Sep |
1 |
| 93 |
20861742 | Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. | 2010 Dec 15 |
1 |
| 94 |
19238117 | In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. | 2009 Apr |
1 |
| 95 |
19239339 | Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. | 2009 Mar 15 |
2 |
| 96 |
19371316 | CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. | 2009 Apr |
1 |
| 97 |
19474465 | Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. | 2009 |
4 |
| 98 |
19531981 | Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese. | 2009 Aug |
4 |
| 99 |
19702527 | Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. | 2009 Sep |
1 |
| 100 |
23675126 | Dyslipidaemia and Intima-Media Thickness of Carotid Arteries in Thirty-Five HIV/AIDS Patients Receiving Highly Active Antiretroviral Therapy. | 2009 Jun |
5 |